Publications by authors named "Maho Nemoto"
Aims: Lenvatinib mesylate (LEN) is an orally administered tyrosine kinase inhibitor used to treat various cancers, including hepatocellular carcinoma (HCC). LEN therapy for HCC is associated with a high incidence of adverse events, including hypertension (HTN). However, the risk factors associated with LEN therapy remain unclear.
View Article and Find Full Text PDFAim: Lenvatinib mesylate (LEN) is an oral tyrosine kinase inhibitor used to treat various cancers, including hepatocellular carcinoma (HCC). HCC treatment with LEN is associated with a very high incidence of adverse events. This study was aimed at investigating the incidence of LEN-induced palmar-planter erythrodysesthesia syndrome (PPES) and its relationship with patient demographics by analyzing clinical laboratory data of LEN-treated patients with HCC.
View Article and Find Full Text PDFArticle Synopsis
- Lenvatinib mesylate (LEN) is used to treat various cancers, including hepatocellular carcinoma (HCC), but can lead to high rates of hypothyroidism among patients.
- A study of 61 HCC patients revealed that 36.1% experienced high-grade hypothyroidism, with a significant correlation found between low eosinophil counts and this condition.
- Factors like noncurrent smoking and eosinophil counts below 150/µL were identified as risks for developing LEN-induced high-grade hypothyroidism.